Skip to main navigation Skip to search Skip to main content

Advances in Pharmacotherapy for Congenital Hyperinsulinism (nov, 10.1007/s40272-025-00727-0, 2025): Advances in Pharmacotherapy for Congenital Hyperinsulinism(Pediatric Drugs, 10.1007/s40272-025-00727-0)

  • Nuria González-Llorens
  • , Daphne Yau
  • , María Clemente León
  • , Huseyin Demirbilek
  • , Indraneel Banerjee
  • , Pratik Shah

Research output: Contribution to journalComment/debate

Abstract

In this article the statements “IB is involved with the patient charities Congenital Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Congenital Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International” in the Conflict of Interest section were incorrect but should have been “IB is involved with the patient charities Children’s Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Children’s Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International.” The original article has been corrected.

Original languageEnglish
Pages (from-to)101
Number of pages1
JournalPaediatric Drugs
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2026

Fingerprint

Dive into the research topics of 'Advances in Pharmacotherapy for Congenital Hyperinsulinism (nov, 10.1007/s40272-025-00727-0, 2025): Advances in Pharmacotherapy for Congenital Hyperinsulinism(Pediatric Drugs, 10.1007/s40272-025-00727-0)'. Together they form a unique fingerprint.

Cite this